As the global biosimilars market opens up, what do physicians faced with choosing between prescribing a brand-name biologic or biosimilar think – and know?

1. What Do Doctors Think
About Biosimilars?
Powered by Small World Social
www.biolink.us

2. In March 2015, the Alliance for
Safe Biologic Medicines
(ASBM), released results from
their survey of 400 US
physicians on biologics
medicines labeling.
Powered by Small World Social
www.biolink.us

3. The web-based survey was
conducted before the FDA approved
Zarxio, the first biosimilar in the US,
and sought the view of
dermatologists, endocrinologists,
oncologists, nephrologists,
neurologists and rheumatologists.
It found…
Powered by Small World Social
www.biolink.us

4. Powered by Small World Social
considered it important for a
biosimilar’s product label to
clearly indicate that it is a
biosimilar.
90% of
correspondents
4Biolink.us

5. Powered by Small World Social
it important for the biosimilar label
to include the biosimilar sponsor’s
analytical data demonstrating its
analytical similarity to the
reference product
82% thought
5Biolink.us

6. Powered by Small World Social
It important that the biosimilar
label includes the clinical data, if
any, submitted to the FDA by the
sponsor again demonstrating that
it is highly similar to the reference
product
83% thought
6Biolink.us

7. Powered by Small World Social
It important that the label explicitly
state that the specific indications
or conditions of use approved for
the originator product that are not
approved for the biosimilar
product
79% found
7Biolink.us

8. In 2013, the ASBM also
surveyed 470 European
physicians, from the United
Kingdom, France, Germany,
Italy and Spain to gauge their
views on non-proprietary
naming of biological
medicines.
Powered by Small World Social
www.biolink.us

9. The survey highlighted the lack of
awareness about biosimilars
amongst prescribing specialist
physicians and the need for further
education.
It found…
Powered by Small World Social
www.biolink.us

10. Powered by Small World Social
said they are ‘familiar’ with
biosimilars, but only have a basic
understanding
54% of
respondents
10Biolink.us

11. Powered by Small World Social
were unable to define biosimilars
20% of the
physicians
11Biolink.us

12. Powered by Small World Social
had never heard of biosimilars
4% of
respondents
12Biolink.us

13. Powered by Small World Social
were ‘very familiar’, with a
complete understanding of
biosimilars
22% of the
physicians
13Biolink.us

14. Meanwhile, a study
conducted by the Tufts
Center of the Study of Drug
Development, at Tufts
University in Boston, found
that…
Powered by Small World Social
www.biolink.us

15. Powered by Small World Social
While the majority of
physicians, 70%,
surveyed said they
would be likely to
prescribe biosimilars to a
new patient, the overall
lack of familiarity with the
new products among
specialist physicians
could slow the uptake of
biosimilars in the U.S.
15Biolink.us

16. Powered by Small World Social
www.biolink.us
Want to read more about
biosimilars?
Visit:
https://www.smallworldsocial.com/biolink/
to get the latest in biosimilar news curated
from around the world